Clinical Trials
16
Active:1
Completed:12
Trial Phases
4 Phases
Phase 1:9
Phase 2:4
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (60.0%)Phase 2
4 (26.7%)Not Applicable
1 (6.7%)Phase 3
1 (6.7%)T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Phase 1
Recruiting
- Conditions
- Glioblastoma MultiformeAstrocytoma, Grade IV
- Interventions
- Biological: Allogeneic cytomegalovirus-specific T cells
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Queensland Institute of Medical Research
- Target Recruit Count
- 58
- Registration Number
- NCT06157541
- Locations
- 🇦🇺
Newro Foundation, Bowen Hills, Queensland, Australia
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
The Prevalence of Rheumatic Heart Disease in School Children in Fiji
- Conditions
- Rheumatic Heart Disease
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2008-10-24
- Lead Sponsor
- Queensland Institute of Medical Research
- Target Recruit Count
- 2000
- Registration Number
- NCT00779662
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Phase 1
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Queensland Institute of Medical Research
- Target Recruit Count
- 8
- Registration Number
- NCT00779337
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
News
No news found